An interventional study of MLD and FMD in Obesity and Overweight (BMI > 25), sponsored by Fondazione Valter Longo. Recruiting at 1 site in Italy. Open to participants aged 14 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Fondazione Valter Longo · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 342 studies in Obesity with a site in Italy — 99 open to participants now, 118 under way, 28 of them phase 3. Obesity · Italy.
Among the 342 studies in Obesity with a site in Italy, this one is the 52nd largest by planned enrollment of the 229 interventional ones that give a count, is one of 29 that started in 2026, is one of 157 with no phase, reaches primary completion later than 108 of the 117 other live ones, and was the 341st registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →99 of the 342 studies in Obesity with a site in Italy are open now. Recruiting first, the newest first:
Istituto Auxologico Italiano · Sites in Italy
Ages 30–70 · Healthy volunteers
Eli Lilly and Company · Sites in Italy, United States, Belgium and 7 more countries
Ages 6–11
Azienda Ospedaliero Universitaria Maggiore della Carita · Sites in Italy
Istituti Clinici Scientifici Maugeri SpA · Sites in Italy
Ages 18+
AstraZeneca · Sites in Italy, United States, Argentina and 13 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 14 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
342 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 9 · Phase 3 49 · Phase 4 15
First in 1999; this study’s year is marked. 29 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 330 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 90 across the 229 interventional studies, 120 across the 112 observational. Of the 183 that completed or were terminated, 14 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
74 of 342 have an industry lead sponsor. The 10 most frequent:
Fondazione Valter Longo is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Fondazione Valter Longo has 4 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
26 of the studies in Obesity with a site in Italy that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT07220642Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | 2027-05-11 |
Add all 26 to your calendar (.ics) → With an account.
Among the 342 studies in Obesity with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Overweight and obesity are increasingly common in adolescents. Italy, and in particular the Campania region, has one of the highest rates of excess weight in children and adolescents in Europe. Dietary approaches that are effective, safe and realistic for teenagers are needed.
This randomized controlled trial will compare two dietary programs with usual diet in adolescents aged 14 to 18 years with overweight or obesity. The study will test whether the Mediterranean Longevity Diet (MLD) and the Fasting Mimicking Diet (FMD) reduce body mass index (BMI) z-score more than continuing the usual diet, while preserving lean mass and normal growth.
The MLD is based on the traditional Mediterranean diet and adapted to the needs of adolescents. It is rich in vegetables, legumes, whole grains, fish, nuts and olive oil, with limited starchy and sugary foods, limited red meat, poultry, eggs and dairy, a moderate protein intake, and all food eaten within a 12-hour window each day. The FMD is a plant-based, low-calorie 5-day meal program that provides vitamins, minerals and essential fatty acids. It is repeated every 3 months, with the usual diet followed between cycles.
A total of 330 adolescents will be randomly assigned in equal numbers (110 per group) to one of three groups: (1) continuing the usual diet and lifestyle (control group), (2) the MLD for 12 months, or (3) the FMD, one 5-day cycle every 3 months, for 12 months. Participants in the control group may choose to follow the MLD or the FMD for 6 months after the first 6 months of the study.
Participants will attend three clinic visits (start of the study, 6 months and 12 months) and will be contacted every month by a nutritionist. At the visits, the research team will measure height, weight, body circumferences, blood pressure and body composition (bioelectrical impedance analysis), collect fasting blood samples and administer questionnaires on diet, lifestyle and sleep. Optional assessments include liver stiffness measurement (FibroScan), pubertal stage assessment, sleep monitoring with a wearable ring, and psychological support sessions.
The main outcome is the change in BMI z-score. Other outcomes include changes in fat mass, lean mass, waist circumference, blood pressure, blood lipids, glucose, HbA1c, insulin resistance, inflammation markers, liver fat index, sleep and diet quality. Safety is closely monitored, with rules for stopping the diet in case of rapid weight loss, fainting, low blood glucose, abnormal blood salts, or signs of eating disorders.
The study is conducted at the Evangelical Hospital Betania in Naples, Italy, in collaboration with the Valter Longo Foundation (Milan) and other clinical centers in Campania.
Childhood and adolescent obesity is a major public health problem. Obesity in youth tends to persist into adulthood and is associated with insulin resistance, dyslipidemia, hypertension, metabolic dysfunction-associated steatotic liver disease and type 2 diabetes. Italy is among the European countries with the highest prevalence of excess weight in children, with particularly high rates in Campania. Fasting-based interventions show promise in adults, but prolonged fasting is difficult and potentially unsafe in adolescents. The Fasting Mimicking Diet (FMD) was designed to produce fasting-like effects (lower IGF-1, glucose and insulin, and higher ketone bodies) while supplying micro- and macronutrients. The Longevity Diet was developed for adults; for adolescents, the investigators adapted the Mediterranean diet, which is better validated in this age group, by adding selected features of the Longevity Diet. These two interventions have not previously been compared in adolescents in a randomized trial.
The study aims to determine the effects of the FMD and the Mediterranean Longevity Diet (MLD), compared with usual diet, on BMI z-score (primary objective) and on body composition and cardiometabolic health markers (secondary objectives). The hypothesis is that both interventions will reduce BMI z-score and fat mass more than the usual diet, preserving lean mass and growth, and improving cardiometabolic markers, with an acceptable safety profile.
Randomized, open-label, three-arm, parallel-group trial in 330 adolescents aged 14 to 18 years, recruited over 24 to 30 months and followed for 12 months from study entry. Participants are recruited by physicians and health professionals in the hospital and in schools. Parents or legal guardians provide informed consent for minors. After a screening call and a baseline visit (eligibility confirmation, consent, baseline assessments), participants are randomized 1:1:1 using the web-based REDCap system, managed by researchers of the Valter Longo Foundation who are not involved in participant care. Randomization is stratified by sex, age group (14-15 vs 16-18 years) and BMI category (25-29.9 vs 30 or more), giving 8 strata, with block randomization within each stratum.
Arm 1 (control): usual diet, exercise and supplements for the first 6 months, with no weight-loss behaviors expected. After the 6-month visit, participants may optionally follow the MLD and/or FMD for 6 months (maximum 3 FMD cycles, one every 3 months).
Arm 2 (MLD, 12 months): protein intake of 0.9 g/kg of ideal body weight, with about half from animal sources (fish 2-3 times per week; red meat, white meat and eggs limited to about once per week) and half from plant sources (legumes, nuts, whole grains); predominantly mono- and polyunsaturated fats; complex carbohydrates from vegetables, whole grains and legumes with low consumption of high-starch foods (pasta, bread, pizza, potatoes, rice), sweetened drinks and snacks, without eliminating any food group; 1-3 servings of fruit per day; 30 g of walnuts, hazelnuts or almonds per day; no more than 3 meals and 1-2 healthy snacks per day; all food consumed within a 12-hour window (time-restricted eating). Vitamins, minerals and omega-3 (EPA/DHA) are added when necessary. Portions are individualized, and energy and nutrient intake is planned to respect age-, sex- and growth-stage requirements. Participants receive written material and individual instructions.
Arm 3 (FMD, 12 months): usual diet, except for a 5-day FMD cycle at baseline and every 3 months (up to 5 cycles in total). The FMD provides about 1000 kcal on day 1 (about 9% protein, 61% fat, 30% carbohydrate) and about 700 kcal per day on days 2-5 (about 8% protein, 52% fat, 40% carbohydrate), using plant-based soups, nut and chocolate bars, crackers, olives, teas, electrolyte drinks and a micronutrient supplement, individually boxed by day. Participants receive urinary ketone strips for self-monitoring of adherence; ketone levels are not a therapeutic target. A safety call is made on day 2-3 of the first cycle, and a cycle is stopped if persistent dizziness, weakness or nausea occurs. A balanced normocaloric diet is resumed after each cycle. Paracetamol may be used for mild headache or myalgia under the supervision of the study pediatrician.
In all active arms, a nutritionist contacts participants and parents monthly (phone or video) to monitor the clinical course and adherence and to support dietary change. Adherence is assessed using a participant calendar and direct verification.
Visit 1 (baseline, T0), Visit 2 (6 months, or at least 7-10 days after the third FMD cycle) and Visit 3 (12 months, or 7-10 days after the last FMD cycle). Assessments include height, weight, waist, hip and other circumferences; blood pressure and heart rate; bioelectrical impedance analysis (BIA) for fat mass, lean mass, phase angle, total and extracellular water and muscle mass; fasting blood tests (complete blood count, glucose, insulin, HOMA-IR, HbA1c, lipid profile, ferritin, ALT, AST, GGT, CRP, uric acid, creatinine, albumin, alkaline phosphatase, TSH, FT3, FT4, cytokines TNF-alpha, IL-6 and IL-1beta, vitamin D); and questionnaires (clinical anamnesis, lifestyle and dietary habits including IPAQ, nutritional questionnaire, Pittsburgh Sleep Quality Index, Berlin Questionnaire, and an FMD questionnaire for arm 3). Blood is drawn at baseline and at 12 months (at 6 months only for the control arm, for a total of 25 mL per draw). Optional components, each requiring specific consent: IGF-1, ghrelin, adipokines, GLP-1, methionine, FGF21 and circulating stem cells; additional blood sampling on day 5 of an FMD cycle; FibroScan transient elastography; Tanner pubertal staging; wearable ring (Oura) sleep monitoring for 2 weeks in a subset of participants with sleep problems (10 per group); and an exploratory psychological support program with the Binge Eating Questionnaire and the EAT-26 (at least 20 participants per group). Participants scoring above clinical cut-offs for eating disorders at baseline are not eligible. Biological samples are coded and stored at -80 C for 10 years at the Betania Hospital.
The primary outcome is the change in BMI z-score from baseline to end of study. Secondary outcomes include changes in fat mass (percentage and absolute), lean body mass, phase angle, body water, muscle mass, body weight, BMI, waist circumference, waist-hip ratio, blood pressure, lipids, glucose, HbA1c, cardiovascular biomarkers, insulin resistance, sleep quality and duration, diet and lifestyle quality, Fatty Liver Index and percentage of total body weight loss. The use of antihypertensive or glucose-lowering medication is also recorded.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
individuals with a family member already included in the study;
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This trial uses a control group to provide robust evidence of the effects of nutritional interventions on the primary and secondary endpoints. Subjects in the control group (arm 1) will be asked to make no changes in dietary programs, exercise programs and nutritional supplements during the first 6 months of the study and before being offered to begin MLD or FMD. The expectation is that subjects will maintain their current weight and not engage in behaviours intended to produce weight loss.
Adolescents follow a Mediterranean Longevity Diet for 12 months, based on the traditional Mediterranean diet and adapted to adolescents: protein intake of 0.9 g/kg of ideal body weight (half plant-based, half from fish and limited animal sources), predominantly unsaturated fats, complex carbohydrates from vegetables, whole grains and legumes with limited starchy and sugary foods, 1-3 servings of fruit and 30 g of nuts per day, and all food eaten within a 12-hour daily window. Portions are individualized and no food group is eliminated. Participants receive written instructions and monthly nutritionist follow-up.
Other: MLD
Adolescents follow their usual diet, except for a 5-day Fasting Mimicking Diet cycle at baseline and then every 3 months for 12 months (up to 5 cycles). The FMD is a plant-based, low-calorie program (about 1000 kcal on day 1 and about 700 kcal on days 2-5) that provides vitamins, minerals and essential fatty acids, delivered in individually boxed daily kits. Participants receive urinary ketone strips for adherence monitoring, a safety call during the first cycle, and monthly nutritionist follow-up.
Other: FMD
Adolescents follow a Mediterranean Longevity Diet for 12 months, based on the traditional Mediterranean diet and adapted to adolescents: protein intake of 0.9 g/kg of ideal body weight (half plant-based, half from fish and limited animal sources), predominantly unsaturated fats, complex carbohydrates from vegetables, whole grains and legumes with limited starchy and sugary foods, 1-3 servings of fruit and 30 g of nuts per day, and all food eaten within a 12-hour daily window. Portions are individualized and no food group is eliminated. Participants receive written instructions and monthly nutritionist follow-up.
Adolescents follow their usual diet, except for a 5-day Fasting Mimicking Diet cycle at baseline and then every 3 months for 12 months (up to 5 cycles). The FMD is a plant-based, low-calorie program (about 1000 kcal on day 1 and about 700 kcal on days 2-5) that provides vitamins, minerals and essential fatty acids, delivered in individually boxed daily kits. Participants receive urinary ketone strips for adherence monitoring, a safety call during the first cycle, and monthly nutritionist follow-up.
Change in BMI z-score from baseline to end of study
BMI z-score (age- and sex-specific, WHO reference) calculated from height and weight measured at the clinic visits. The change from baseline is compared between each intervention arm (Mediterranean Longevity Diet, Fasting Mimicking Diet) and the control arm.
Time frame: From baseline to the end of study, 12 months
Change in fat mass
Percentage (%) and absolute fat mass (kg) measured by bioelectrical impedance analysis (BIA).
Time frame: From baseline to the end of study, 12 months
Change in lean body mass and muscle mass
Lean body mass and muscle mass (kg) measured by BIA, to assess preservation of lean tissue during the interventions.
Time frame: From baseline to the end of study, 12 months
Change in phase angle
Phase angle (°), measured by BIA.
Time frame: From baseline to the end of study, 12 months
Change in body weight and BMI
Body weight (kg) and BMI (kg/m²) measured at the clinic.
Time frame: From baseline to the end of study, 12 months
Change in waist circumference and waist-to-hip ratio
Waist and hip circumferences (cm) measured by trained staff, and waist-to-hip ratio calculated from them.
Time frame: From baseline to the end of study, 12 months
Change in blood pressure
Systolic and diastolic blood pressure (mmHg), measured three times at 2-minute intervals in the sitting position, with heart rate recorded at each measurement.
Time frame: From baseline to the end of study, 12 months
Change in serum lipids
Fasting total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides (mg/dL).
Time frame: From baseline to the end of study, 12 months
Change in fasting glucose
Fasting glucose (mg/dL)
Time frame: From baseline to the end of study, 12 months
Change in inflammatory and cardiovascular biomarkers
C-reactive protein (mg/L), uric acid (mg/dL) and the cytokines TNF-alpha, IL-6 and IL-1beta (pg/mL) measured on fasting blood samples.
Time frame: From baseline to the end of study, 12 months
Change in Fatty Liver Index (FLI)
FLI calculated from BMI, waist circumference, triglycerides and GGT, as a non-invasive estimate of hepatic steatosis.
Time frame: From baseline to the end of study, 12 months
Change in sleep quality and duration
Sleep quality assessed with the Pittsburgh Sleep Quality Index in participants with sleep problems
Time frame: From baseline to the end of study, 12 months
Change in total body water and extracellular water
total body water (%) and extracellular water (%) measured by BIA.
Time frame: From baseline to the end of study, 12 months
Change in percentage of total body weight loss (%TBWL)
%TBWL is calculated as the percentage change in body weight from baseline.
Time frame: From baseline to the end of study, 12 months
Change in insulin resistance
fasting insulin (µU/mL)
Time frame: From baseline to the end of study, 12 months
Change in glucose metabolism
HOMA-IR and glycated hemoglobin (%).
Time frame: From baseline to the end of study, 12 months
PDFs hosted by the registry, ClinicalTrials.gov.
Started Nov 2026 (actual). Primary completion is estimated for Nov 2029, 36 months after the start.
Of 3,690 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 36 months is above that.
Counting every sponsor, half of 3,853 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione Valter Longo